lenalidomide
not tagged
 presenting during annual meeting. activity and tolerability of lenalidomide is enhanced following low-dose continuous percutaneous deliver compared to once daily dosing in an ncih929 mm xenograft model in scid mice. #ims2022 
Transforming therapies with proprietary dermal technology, so people with cancer can receive continuous treatment to live better, longer.